肥厚型心肌病最大室壁厚度测量:生物标志物变异性及其对临床诊疗的影响
该研究通过20中心全球网络选取17对高质量超声与心脏磁共振配对数据集,在6次心脏会议上呈现给70名有经验的读片者测量最大室壁厚度,发现两种模态的读片者间变异均较大、模态间一致性低;将超声测量的±20%变异应用于769例多中心肥厚型心肌病患者的欧洲心脏病学会5年心源性猝死风险算法,19.5%的患者风险被重新分类,可能导致每7例中1例不恰当的ICD决策。
要点
- 超声与心脏磁共振测得的肥厚型心肌病最大室壁厚度读片者间变异大,模态间一致性低。
- 超声最大室壁厚度±20%的测量变异可使欧洲心脏病学会算法对19.5%的患者重新分类风险。
- 该变异可能导致每7例肥厚型心肌病患者中1例ICD植入决策不当。
核心结论
- 在最优图像和有经验读片者条件下,肥厚型心肌病最大室壁厚度作为生物标志物仍存在高度读片者间变异,用于ICD植入决策时应谨慎。
研究设计与样本
- 20中心全球网络提供肥厚型心肌病患者配对的超声与心脏磁共振数据集,从中选出17对最高质量数据集,随机排序为7对在6次心脏会议上呈现给有经验的读片者测量最大室壁厚度;另用769例单独招募的多中心肥厚型心肌病患者评估测量变异对ICD植入决策的影响。
诊断标准与关键数值
- 超声最大室壁厚度读片者间百分比变异范围为-59%至117%(标准差±20%),心脏磁共振为-61%至52%(标准差±11%)。
- 超声与心脏磁共振两种模态间一致性低:测量标准误4.8 mm(95%CI 4.3 mm-5.2 mm),r=0.56(相关性中等)。
- 将超声最大室壁厚度±20%的变异应用于欧洲心脏病学会5年心源性猝死风险算法,19.5%的患者风险被重新分类。
- 风险重新分类导致每7例肥厚型心肌病患者中1例ICD决策不当:8.7%的患者尽管可能为低风险仍被建议植入ICD,6.8%的患者尽管为中或高风险仍未获ICD植入建议。
临床应用与阅片要点
- 作者认为最大室壁厚度作为肥厚型心肌病ICD植入决策依据时应谨慎使用,并指出当前管理学会的肥厚型心肌病推荐需更好的标准化以改善临床决策。
局限性
- 作者指出需要当前管理学会在肥厚型心肌病推荐中开展更好的标准化工作以改善临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The aim of this study was to define the variability of maximal wall thickness (MWT) measurements across modalities and predict its impact on care in patients with hypertrophic cardiomyopathy (HCM).
BACKGROUND: Left ventricular MWT measured by echocardiography or cardiovascular magnetic resonance (CMR) contributes to the diagnosis of HCM, stratifies risk, and guides key decisions, including whether to place an implantable cardioverter-defibrillator (ICD).
METHODS: A 20-center global network provided paired echocardiographic and CMR data sets from patients with HCM, from which 17 paired data sets of the highest quality were selected. These were presented as 7 randomly ordered pairs (at 6 cardiac conferences) to experienced readers who report HCM imaging in their daily practice, and their MWT caliper measurements were captured. The impact of measurement variability on ICD insertion decisions was estimated in 769 separately recruited multicenter patients with HCM using the European Society of Cardiology algorithm for 5-year risk for sudden cardiac death.
RESULTS: MWT analysis was completed by 70 readers (from 6 continents; 91% with >5 years' experience). Seventy-nine percent and 68% scored echocardiographic and CMR image quality as excellent. For both modalities (echocardiographic and then CMR results), intramodality inter-reader MWT percentage variability was large (range -59% to 117% [SD ±20%] and -61% to 52% [SD ±11%], respectively). Agreement between modalities was low (SE of measurement 4.8 mm; 95% CI 4.3 mm-5.2 mm; r = 0.56 [modest correlation]). In the multicenter HCM cohort, this estimated echocardiographic MWT percentage variability (±20%) applied to the European Society of Cardiology algorithm reclassified risk in 19.5% of patients, which would have led to inappropriate ICD decision making in 1 in 7 patients with HCM (8.7% would have had ICD placement recommended despite potential low risk, and 6.8% would not have had ICD placement recommended despite intermediate or high risk).
CONCLUSIONS: Using the best available images and experienced readers, MWT as a biomarker in HCM has a high degree of inter-reader variability and should be applied with caution as part of decision making for ICD insertion. Better standardization efforts in HCM recommendations by current governing societies are needed to improve clinical decision making in patients with HCM.
引用
- Captur G, Manisty CH, Raman B, et al. Maximal Wall Thickness Measurement in Hypertrophic Cardiomyopathy: Biomarker Variability and its Impact on Clinical Care. JACC Cardiovasc Imaging. 2021. PMID: 34147459. doi:10.1016/j.jcmg.2021.03.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。